ORKA
Oruka Therapeutics, Inc.
NASDAQ: ORKA · HEALTHCARE · BIOTECHNOLOGY
$68.10
-7.96% today
Updated 2026-04-29
Market cap
$3.42B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.85
Dividend yield
—
52W range
$9 – $91
Volume
1.2M
Oruka Therapeutics, Inc. (ORKA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.89M | $46.86M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $0.00 |
| Revenue growth (YoY) | — | +1105.3% | -100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cost of revenue | $3.18M | $2.34M | — | — | $338000.00 | $2.92M | $43000.00 | $26000.00 | $12000.00 | $19000.00 | $24000.00 | $27000.00 | $22000.00 | $89000.00 | $93000.00 | $91000.00 | $114000.00 | $111000.00 | $27000.00 | $83000.00 |
| Gross profit | $706000.00 | $44.52M | — | — | $-338000.00 | $-2.92M | $-43000.00 | $-26000.00 | $-12000.00 | $-19000.00 | $-24000.00 | $-27000.00 | $-22000.00 | $-89000.00 | $-93000.00 | $-91000.00 | $-114000.00 | $-111000.00 | $-27000.00 | $-83000.00 |
| Gross margin | 18.2% | 95.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| R&D | $89.37M | $42.65M | $11.03M | $10.01M | $3.11M | — | $1.09M | $2.93M | $5.63M | $7.06M | $12.35M | $14.08M | $4.24M | $1.83M | $4.99M | $13.83M | $4.46M | $1.01M | $75.06M | $100.64M |
| SG&A | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $21.41M |
| Operating income | $-140.57M | $-16.55M | $-19.49M | $-22.85M | $-9.18M | $-7.36M | $-4.32M | $-6.94M | $-9.69M | $-11.46M | $-16.61M | $-18.71M | $-8.12M | $-5.81M | $-9.77M | $-19.34M | $-9.84M | $-7.30M | $-88.12M | $-122.05M |
| Operating margin | -3615.6% | -35.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | $-129.01M | $-9.86M | $-19.03M | $-10.78M | $-8.07M | $-4.76M | $-4.27M | $-6.91M | $-9.68M | $-11.43M | $-16.42M | $-18.52M | $-7.94M | $-5.55M | $-9.64M | $-19.23M | $-9.81M | $-5.23M | $-82.23M | $-121.97M |
| EBITDA margin | -3318.1% | -21.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBIT | $-132.19M | $-12.20M | $-19.25M | $-11.23M | $-8.41M | $-5.36M | $-4.32M | $-6.94M | $-9.69M | $-11.45M | $-16.44M | $-18.55M | $-7.96M | $-5.64M | $-9.74M | $-19.32M | $-9.93M | $-5.34M | $-82.26M | $-122.05M |
| Interest expense | $588000.00 | $103000.00 | $178000.00 | $185000.00 | $8000.00 | $5000.00 | $3000.00 | — | — | — | — | — | — | $7000.00 | $9000.00 | — | — | — | $1.47M | $0.00 |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-132.78M | $-12.30M | $-19.43M | $-9.14M | $-8.42M | $-5.36M | $-4.32M | $-6.94M | $-9.69M | $-11.45M | $-16.44M | $-18.49M | $-7.93M | $-5.48M | $-9.74M | $-19.32M | $-9.93M | $-5.34M | $-83.72M | $-105.43M |
| Net income growth (YoY) | — | +90.7% | -58.0% | +53.0% | +7.9% | +36.3% | +19.5% | -60.6% | -39.6% | -18.1% | -43.7% | -12.4% | +57.1% | +30.9% | -77.6% | -98.4% | +48.6% | +46.2% | -1468.2% | -25.9% |
| Profit margin | -3415.0% | -26.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |